PhoenixBio Co., Ltd. (6190.T) develops and provides specialized contract research services for drug discovery and development, primarily utilizing its proprietary PXB-mouse, a chimeric mouse model with a highly humanized liver containing up to 90% human hepatocytes. The company offers PXB-mouse services for in vivo studies including drug metabolism and pharmacokinetics (DMPK), toxicology, viral hepatitis (HBV and HBV/HDV), nonalcoholic steatohepatitis (NASH/MASH)/NAFLD, gene-based therapeutics, oligonucleotide therapies, and custom transplantations; PXB-cells, fresh or cryopreserved human hepatocytes derived from PXB-mice for in vitro studies; and Tg & KO animal services with custom transgenic animals. It operates production and research facilities in Japan, the United States, and internationally, producing over 4,000 PXB-mice annually with consistent quality for global pharmaceutical and academic clients.
Founded in 2002 and headquartered in Higashi-Hiroshima City, Japan, PhoenixBio maintains subsidiaries including PhoenixBio USA Corporation in New York and CMHL Consortium LLC in Delaware, USA, supporting project management, sales, and collaborative research consortia with pharmaceutical leaders.
In February 2025, PhoenixBio entered a business partnership with TOPPAN Holdings Inc. to co-develop and commercialize artificial 3D liver tissue models combining TOPPAN's invivoid 3D cell culture technology with PhoenixBio's PXB-cells, enhancing applications in drug discovery, personalized cancer treatment, high-sensitivity liver toxicity evaluation, and translational research. The company continues active global engagement, with recent announcements for presentations on PXB-mouse and PXB-Shizuku technologies at conferences including CTRMS 2025, European Society of Gene and Cell Therapy, and ISSX 2025 in September 2025.